Biologics : Targets & Therapy最新文献

{"title":"Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy.","authors":"Rashid Abdel-Razeq, Asem Mansour, Maha Barbar, Mayada Abu Shanap, Baha Sharaf, Faris Tamimi, Razan Mansour, Adel Muhanna, Yazan Al-Othman, Hazem Hammad, Mohammad Shakhatreh, Suleiman Mahafdah, Hira Bani Hani, Hikmat Abdel-Razeq","doi":"10.2147/BTT.S543427","DOIUrl":"10.2147/BTT.S543427","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic cancer is one of the most lethal malignancies, with a five-year survival rate rarely exceeding 10%. Due to its asymptomatic onset, it is frequently diagnosed at an advanced and often inoperable stage. This review assesses current strategies for early detection, including genomic testing, advanced imaging technologies, and biomarker-based platforms, with a focus on their clinical utility and integration into surveillance protocols.</p><p><strong>Methods: </strong>This narrative review synthesizes findings from published literature on germline genetic testing (GGT), imaging modalities such as endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI), and the latest advancements in biomarker discovery and molecular diagnostics for early pancreatic cancer detection. International guidelines and emerging evidence were assessed to explore their clinical implementation and challenges.</p><p><strong>Results: </strong>Although EUS and MRI show promise for detecting early pancreatic lesions, both require specialized expertise and are limited by accessibility and cost. Emerging blood-based biomarkers and molecular platforms, however, may offer a more scalable, non-invasive alternative for detecting pancreatic cancer at earlier, treatable stages.</p><p><strong>Conclusion: </strong>Early detection of pancreatic cancer is pivotal to improving survival outcomes. While imaging techniques and genetic screening have enhanced risk stratification and early diagnosis in high-risk populations, novel biomarker and molecular testing platforms offer an accessible and scalable solution. Future efforts should focus on validating these assays in large-scale prospective cohorts and integrating them into screening protocols, particularly for individuals with genetic susceptibility.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"511-523"},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.","authors":"Chuanhui Xu, Shiow-Ing Wang, Ying Ying Leung, James Cheng-Chung Wei","doi":"10.2147/BTT.S532668","DOIUrl":"10.2147/BTT.S532668","url":null,"abstract":"<p><strong>Objective: </strong>We aim to evaluate the malignancy risk between Janus kinase inhibitors (JAKi) users and tumor necrosis factor inhibitors (TNFi) users in rheumatoid arthritis (RA) patients, using a large real-world electronic health record database (TriNetX).</p><p><strong>Methods: </strong>In this retrospective cohort study, we identified adult RA patients initiating JAKi or TNFi therapy between January 1, 2018, and December 31, 2022, within the TriNetX global federated network. The hazard ratio (HR) and confidence intervals (CI) of incident-specific cancers, overall cancer incidence, and all-cause mortality, were calculated between the propensity score matched JAKi and TNFi cohorts. The probability of the outcome of interest was estimated using the Kaplan-Meier analysis.</p><p><strong>Results: </strong>After propensity score matching, there were 4045 each in JAKi or TNFi user cohorts. The mean (standard deviation) age was 57.7 (13.3) and 57.6 (13.9) years, 81.4% and 80.8% were female, and median (interquartile range) follow-up time 3.69 (2.61) years vs 3.69 (2.68) years, in the JAKi and the TNFi cohorts, respectively. No significant differences were observed in risks of overall cancer incidence and all-cause mortality between the two cohorts. JAKi users had a reduced risk of incident digestive organ cancers compared with TNFi users (adjusted HR: 0.599, 95% CI: 0.439-0.817), mainly observed among females. The risks of incident respiratory and intrathoracic organs cancers were increased in JAKi users compared to TNFi users among females (adjusted HR: 2.582, 95% CI: 1.109-6.011) but not in males.</p><p><strong>Conclusion: </strong>In a large real-world database, we did not find an increased risk of overall cancer incidence in JAKi compared to TNFi users among RA patients. JAKi users had a lower risk of incident digestive organs cancers, and a higher risk of respiratory cancer in females, when compared with TNFi users.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"525-538"},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Potential of Compounds with High Affinity to BAG2 in Inhibiting Keloid Disease.","authors":"Yinmin Wang, Zhaoqi Yuan, Renpeng Zhou, Lin Lu, Xiuxia Wang, Jun Yang","doi":"10.2147/BTT.S533286","DOIUrl":"10.2147/BTT.S533286","url":null,"abstract":"<p><strong>Purpose: </strong>Targeting the distinct genetic and protein expression profiles of keloids necessitates the identification of novel therapeutic targets. This study was aimed to elucidate the role of Bcl-2-associated athanogene 2 (BAG2) in keloid pathology and identify compounds with high-affinity to BAG2.</p><p><strong>Patients and methods: </strong>Cell migration, and cell proliferation assays, along with flow cytometry, were used to evaluate the effects of BAG2 on keloid fibroblasts (KFs) derived from tissue samples of patients with abdominal or chest keloids. Additionally, histological examinations and Western blotting were performed to investigate BAG2's role in keloids. Surface plasmon resonance (SPR) was employed to identify compounds with high-affinity to BAG2, and the effects of these compounds on keloids was assessed.</p><p><strong>Results: </strong>Inhibition of BAG2 significantly decreased collagen deposition, cell proliferation and migration in keloid tissues. The modulatory effect of BAG2 on these processes appears to be mediated partly by the MEK signaling pathway. Among the tested compounds, Bazedoxifene acetate and Ponesimod showed high affinity for BAG2 and demonstrated a more pronounced inhibitory effect on collagen deposition of the keloid tissues than other candidates.</p><p><strong>Conclusion: </strong>This study revealed the pathogenic role of BAG2 in keloid and identified compounds with high-affinity to BAG2, Bazedoxifene acetate and Ponesimod. The therapeutic capabilities of these compounds demonstrated their potential to improve therapeutic strategies for localized, targeted treatment to keloids.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"497-510"},"PeriodicalIF":3.4,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144941861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What's New and What's Next in Fecal Microbiota Transplantation?","authors":"Hussein Baydoun, Naushair Hussain, Ken O Wu, Colleen R Kelly, Monika Fischer","doi":"10.2147/BTT.S486372","DOIUrl":"https://doi.org/10.2147/BTT.S486372","url":null,"abstract":"<p><p>Fecal microbiota transplantation (FMT) has evolved from a niche therapy to a cornerstone in the treatment of recurrent <i>Clostridioides difficile</i> infection (rCDI). Initially introduced in the 1950s, its relevance has surged with the emergence of virulent and antibiotic-resistant <i>C. difficile</i> strains. In recent years, the FDA approved two standardized microbiota-based therapeutics-Rebyota™ (fecal microbiota, live-jslm) and Vowst™ (fecal microbiota spores, live-brpk)-for rCDI prevention. Multiple pivotal trials support the efficacy and safety of both traditional FMT and the FDA-approved prescription FMTs, with sustained response rates surpassing 80% in select populations. In parallel, live biotherapeutic products (LBPs)-donor independent, well-defined microbial consortia produced in laboratory setting are under development. Examples include VE303 and NTCD-M3, a single non-toxigenic C. difficile strain (M3). Beyond the FDA approved therapeutics, conventional FMT is gaining traction as a potential treatment for severe or fulminant CDI, especially in patients not responding to antibiotics and ineligible for surgery. Investigational indications include decolonizing multidrug-resistant organisms and treatment of noninfectious conditions such as inflammatory bowel disease, irritable bowel syndrome, liver disease, and metabolic syndrome. Given the differing pathophysiology of these conditions, a tailored approach supported by rigorous clinical trials is essential. Although there is a growing shift, particularly in the United States, toward the use of FDA-approved FMTs, global practices remain heterogeneous, with conventional FMT still widely employed. Meanwhile, regulatory pathways and clinical guidelines for microbiota-derived biologics and live biotherapeutic products continue to evolve. In this manuscript, we provide an update on the emerging use of FDA-approved prescription microbiota-derived therapeutics for the prevention of rCDI, review data on investigational agents including both donor dependent and donor independent microbial products, and summarize current evidence on the use of conventional FMT for indications beyond prevention of rCDI.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"481-496"},"PeriodicalIF":3.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144941904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Oncogenic and Immunological Implications of YTHDF1 in Ovarian Cancer.","authors":"Bo Yin, Huijuan Zhou","doi":"10.2147/BTT.S542488","DOIUrl":"10.2147/BTT.S542488","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian cancer (OC) ranks among the most lethal and aggressive gynecological malignancies. Identifying novel molecular targets is crucial for improving early diagnosis and developing effective therapies. Despite advancements in immunotherapy, its efficacy in OC remains limited due to the absence of well-defined immune-related molecular targets.</p><p><strong>Methods: </strong>This study offers a comprehensive analysis of YTHDF1, combining multi-omics-based bioinformatics approaches with in vitro and in vivo experimental validation to elucidate its functional role and significance in the progression and treatment of OC.</p><p><strong>Results: </strong>Our findings reveal that YTHDF1 is significantly upregulated in OC and correlates with poor clinical outcomes. Functional assays confirmed its oncogenic properties, while pathway analyses highlight its involvement in critical tumor-promoting signaling pathways. Importantly, we identified a potential link between YTHDF1 expression and the tumor immune landscape, suggesting its role in modulating immune cell infiltration and driving immunosuppression. Additionally, both computational and in vivo evidence underline the relevance of YTHDF1 in influencing immunotherapeutic responsiveness and chemosensitivity in OC. Mechanistically, we discovered for the first time that YTHDF1 can be encapsulated within tumor-derived exosomes, contributing to the polarization of macrophages toward the immunosuppressive M2a phenotype.</p><p><strong>Discussion: </strong>These findings position YTHDF1 as a promising prognostic biomarker and therapeutic target for OC. Its role in shaping an immunosuppressive microenvironment and mediating chemoresistance underscores its potential in enhancing immunotherapy and improving chemotherapy outcomes.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"443-462"},"PeriodicalIF":3.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning.","authors":"Nickoulet Babaei, Minka Gill, Mireya Cervantes, Dahyeon Kim, Seanna Yang, Jashin J Wu","doi":"10.2147/BTT.S532526","DOIUrl":"10.2147/BTT.S532526","url":null,"abstract":"<p><p>Brodalumab is a monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), offering a novel approach to treating moderate-to-severe psoriasis. By blocking IL-17RA, brodalumab inhibits the activity of multiple pro-inflammatory IL-17 isoforms, including IL-17A, IL-17F, and IL-17C, which are critical in the pathogenesis of psoriasis. This review synthesizes data from Phase I-IV clinical trials and real-world studies to provide a comprehensive overview of brodalumab's efficacy, safety, and clinical role in the treatment of moderate-to-severe psoriasis. Clinical trial data consistently demonstrate its rapid onset of action, high rates of skin clearance, and durability of response. Real-world evidence supports its effectiveness in treatment-resistant cases and among patients with previous biologic failures. Safety considerations include the need for monitoring suicidality, although no causal relationship has been confirmed. Despite being one of the most effective biologic agents available for psoriasis, brodalumab remains underutilized, highlighting the need for improved awareness of its potential clinical advantages. Further research is warranted to better define its role in treatment algorithms and to assess long-term outcomes in broader patient populations.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"415-422"},"PeriodicalIF":5.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marstacimab for the Treatment of Hemophilia A or B.","authors":"Johnny Mahlangu","doi":"10.2147/BTT.S500480","DOIUrl":"10.2147/BTT.S500480","url":null,"abstract":"<p><p>Hemophilia A and B, caused by deficiencies of coagulation factors VIII or IX, result in impaired thrombin generation with consequent spontaneous or trauma-related bleeding, particularly hemarthroses. Although prophylactic factor replacement therapy remains the global standard of care for hemophilia, it has significant limitations, including intravenous administration, breakthrough bleeding, inhibitor development, and deteriorating arthropathy despite prophylaxis. Marstacimab, an IgG1 monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), represents a novel non-factor approach. Marstacimab restores thrombin generation via the extrinsic pathway, bypassing intrinsic pathway deficiencies and offering prophylactic benefit independent of inhibitor status. Clinical evaluation across Phase 1b/2 and Phase 3 (BASIS) trials and ongoing extension studies has demonstrated robust efficacy. In Phase 3, marstacimab reduced annualized bleed rates by 91.6% compared with episodic treatment and was non-inferior to factor prophylaxis. Bleed control was sustained though zero-bleed outcomes were not uniformly achieved. Pharmacokinetic data support once-weekly fixed dosing independent of body weight, simplifying administration and potentially improving adherence. Across all studies, marstacimab demonstrated a favorable safety profile. Injection site reactions were the most common adverse events, while anti-drug antibodies, including neutralizing types, were transient and without clinical impact. Marstacimab, the first FDA-approved anti-TFPI antibody for prophylaxis in hemophilia A and B without inhibitors, addresses key unmet needs, particularly for hemophilia B patients lacking subcutaneous (SC) prophylaxis options. Its novel mechanism, ease of administration, and sustained efficacy position it as a significant therapeutic advance. Marstacimab's exact role in the hemophilia treatment armamentarium is yet to be established with the availability of coming real-world experience data. The long-term studies remain essential to fully demonstrate its role, especially in populations with inhibitors and in the context of evolving non-factor therapies. This review summarises currently available clinical data and contextualises these in light of other treatments in hemophilia.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"379-386"},"PeriodicalIF":5.3,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease.","authors":"Ferdinando D'Amico, Sarah Bencardino, Fernando Magro, Axel Dignass, Ana Gutiérrez Casbas, Bram Verstockt, Ailsa Hart, Alessandro Armuzzi, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.2147/BTT.S530354","DOIUrl":"10.2147/BTT.S530354","url":null,"abstract":"<p><p>Guselkumab, a selective interleukin-23 (IL-23) inhibitor, has emerged as a promising biologic therapy for the management of patients with moderate-to-severe Crohn's disease (CD) and has been recently approved for its treatment. Unlike conventional therapies, guselkumab offers a different mechanism of action by selectively inhibiting IL-23, a key cytokine implicated in the pathogenesis of CD. IL-23 drives intestinal inflammation through activation of the Th17 cell pathway and other immune processes, positioning IL-23 inhibition as a critical therapeutic approach. In randomized Phase III clinical trials, guselkumab proved to be effective in inducing clinical and endoscopic remission both in patients naive to biologics and in patients already exposed to advanced therapies. Furthermore, no safety issues were found, supporting the well-characterized safety in other indications and its use in clinical practice also in IBD. Moreover, guselkumab has been approved for other immunomediated inflammatory disease moderate to severe plaque psoriasis, psoriatic arthritis and ulcerative colitis. This review summarizes the available evidence on efficacy and safety of guselkumab in patients with moderate to severe CD, focusing on its positioning in the treatment algorithm.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"351-363"},"PeriodicalIF":5.3,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting CREBRF in Cancer: Mechanistic Insights and Future Directions.","authors":"Baixue Lv, Dongdong Zhang","doi":"10.2147/BTT.S522325","DOIUrl":"10.2147/BTT.S522325","url":null,"abstract":"<p><p>Luman/CREB3 recruitment factor (LRF), also known as CREBRF, was initially identified as a cellular binding protein of Luman through yeast two-hybrid screening of a human brain cDNA library. CREBRF plays a critical role in various biological processes, with its functions garnering significant attention in the field of oncology. Notably, CREBRF is involved in endoplasmic reticulum (ER) stress and regulates the unfolded protein response (UPR), leading to an accumulation of misfolded proteins. This can ultimately result in cellular dysfunction, apoptosis, and even tumorigenesis. In solid tumors, hypoxia is a common condition, and CREBRF has been implicated in hypoxia-induced autophagy, which promotes tumor cell proliferation. Depending on the tumor type and microenvironment, CREBRF exerts diverse effects by modulating distinct signaling pathways. This review summarizes CREBRF's involvement in ER stress, cell cycle regulation, autophagy, and the mechanisms through which it influences tumor initiation and progression across various cancer types. Furthermore, the potential of CREBRF as a therapeutic target in cancer treatment is discussed, providing insights into future research and clinical applications.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"341-350"},"PeriodicalIF":5.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey.","authors":"Naim Ata, Hasan Satış, Orhan Küçükşahin, Erdem Karabulut, Gizem Ayan, Abdulsamet Erden, Emre Bilgin, Berkan Armağan, Duygu Tecer, Hakan Babaoğlu, Alper Sarı, Levent Kılıç, Mustafa Mahir Ülgü, Mustafa Okan Ayvalı, Şuayip Birinci, Umut Kalyoncu","doi":"10.2147/BTT.S507132","DOIUrl":"10.2147/BTT.S507132","url":null,"abstract":"<p><strong>Objective: </strong>There are national and international guidelines on the optimal use of disease-modifying anti-rheumatic drugs. In this study, we aimed to provide critical insights into the real-world efficacy and adherence of these DMARDs, providing a data-driven basis for optimizing treatment paradigms for RA within the national healthcare framework.</p><p><strong>Methods: </strong>This nationwide cohort study utilized data from the Turkish Ministry of Health National Electronic Database, known as E-Pulse between January 2016 and December 2022. In this analysis, cases of RA were identified using ICD-10 codes two times at least 30 days apart Treatment prescriptions were recorded based on their prescription at baseline and follow-up.</p><p><strong>Results: </strong>There were a total of 347,902 RA (79.5% female) patients in the E-Pulse system. The mean (SD) age of RA patients was 59.1 (14.8) years Methotrexate and sulfasalazine (35.1% vs 30.5%, OR 95% CI 0.81 usage was more common in men and hydroxychloroquine was more common in women 46.764 (13.4%) patients were prescribed bDMARD and/or tsDMARD 494.499 times. AntiTNF drugs are the most commonly prescribed drugs. This is followed by B-cell blockers, JAK inhibitors, anti-IL6 and T-cell blockers.</p><p><strong>Conclusion: </strong>Turkish national health database highlights the widespread use of synthetic DMARDs in treating rheumatoid arthritis (RA). While traditional DMARDs like methotrexate and hydroxychloroquine are favored the cautious use of advanced therapies, particularly anti-TNFs, suggests a potential for optimizing treatment protocols.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"19 ","pages":"331-339"},"PeriodicalIF":5.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}